Zobrazeno 1 - 10
of 108
pro vyhledávání: '"Thomas N. Kakuda"'
Autor:
Catherine Orrell, Franco Felizarta, André Nell, Thomas N. Kakuda, Ludo Lavreys, Steven Nijs, Lotke Tambuyzer, Rodica Van Solingen-Ristea, Frank L. Tomaka
Publikováno v:
AIDS Research and Treatment, Vol 2015 (2015)
Objectives. TEACH (NCT00896051) was a randomized, open-label, two-arm Phase II trial to investigate the pharmacokinetic interaction between etravirine and atazanavir/ritonavir and safety and efficacy in treatment-experienced, HIV-1-infected patients.
Externí odkaz:
https://doaj.org/article/8007d414adb549a5a95e5d63499f93a4
Autor:
Thomas N. Kakuda, Atef Halabi, Gernot Klein, Madhu Sanga, Carine Guinard‐Azadian, Monika Kowalik, Katja Nedoschinsky, Julius Nangosyah, Emmanuel Njumbe Ediage, Vera Hillewaert, Peter Verboven, Ivo Goris, Jan Snoeys, Martyn Palmer, Michael Biermer
Publikováno v:
The Journal of Clinical Pharmacology. 63:732-741
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cba13bd19fd72820553526ce012f9e1d
https://doi.org/10.1002/jcph.2214
https://doi.org/10.1002/jcph.2214
Autor:
Haiyan, Li, Xiaoye, Niu, Yu, Zhang, Danning, Zhang, Yanqing, Zhang, Liqun, Wang, Yongqing, Miao, Yanxin, Jiang, Jia, Ji, Qiaoqiao, Chen, Xiaoyun, Wu, Emmanuel Njumbe, Ediage, Thomas N, Kakuda, Michael, Biermer
Publikováno v:
Clinical Pharmacology in Drug Development. 12:175-180
JNJ-73763989, composed of the 2 short-interfering RNA triggers JNJ-73763976 and JNJ-73763924, targets all hepatitis B virus messenger RNAs, thereby reducing all viral proteins. In this phase 1, single-site, open-label, parallel-group, randomized stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9b89cdfc52cdfd43a5f293f58d98793
https://doi.org/10.1002/cpdd.1197
https://doi.org/10.1002/cpdd.1197
Autor:
Joris, Vandenbossche, Jeysen, Yogaratnam, Vera, Hillewaert, Freya, Rasschaert, Willem, Talloen, Jeike, Biewenga, Jan, Snoeys, Thomas N, Kakuda, Martyn, Palmer, Julius, Nangosyah, Michael, Biermer
Publikováno v:
Clinical Pharmacology in Drug Development. 11:1419-1429
The capsid assembly modulator JNJ-56136379 (bersacapavir) disrupts hepatitis B virus replication. It is metabolized via cytochrome P450 (CYP) 3A, but little is known about the drug-drug interactions of JNJ-56136379 when combined with drugs that inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e46aeb60d5492b55a4cdaa1a03186527
https://doi.org/10.1002/cpdd.1164
https://doi.org/10.1002/cpdd.1164
Autor:
Sushmita Mukherjee Chanda, Christian Schwabe, E.J. Gane, Megha Patel, Oliver Lenz, Jan Snoeys, Jeysen Yogaratnam, Christopher Westland, Jennifer Vuong, Willem Talloen, Thomas N. Kakuda, Pieter Van Remoortere, John Fry
Publikováno v:
Antiviral therapy. 26(1-2)
Background Pharmacokinetics and safety of JNJ-64530440, a hepatitis B virus capsid assembly modulator producing normal empty capsids (CAM-N), in healthy volunteers were evaluated. Methods This Phase I study (NCT03439488) was a double-blind, randomise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f7ca45ddd502f62d3dc189589442d5e
https://pubmed.ncbi.nlm.nih.gov/35485346
https://pubmed.ncbi.nlm.nih.gov/35485346
Autor:
Ed Gane, Man-Fung Yuen, Thomas N Kakuda, Tetsuro Ogawa, Yasushi Takahashi, Nele Goeyvaerts, Isabelle Lonjon-Domanec, Tamisha Vaughan, Thomas Schluep, James Hamilton, Emmanuel Njumbe Ediage, Vera Hillewaert, Jan Snoeys, Oliver Lenz, Willem Talloen, Michael Biermer
Publikováno v:
Antiviral Therapy. 27:135965352210938
Background JNJ-73763989 comprises two hepatitis B virus (HBV)-specific, liver-targeted N-galactosamine-conjugated short interfering RNA triggers, JNJ-73763976 and JNJ-73763924. JNJ-73763989 pharmacokinetics, safety and tolerability were assessed in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a183962973290deca1b3df39e926e0e
https://doi.org/10.1177/13596535221093856
https://doi.org/10.1177/13596535221093856
Autor:
Ed J. Gane, Christian Schwabe, Elina Berliba, Pisit Tangkijvanich, Alina Jucov, Nelea Ghicavii, Thierry Verbinnen, Oliver Lenz, Willem Talloen, Thomas N. Kakuda, Chris Westland, Megha Patel, Jeysen Z. Yogaratnam, Leonard Dragone, Pieter Van Remoortere
Publikováno v:
The Journal of antimicrobial chemotherapy. 77(4)
Objectives We investigated JNJ-64530440 (a hepatitis B virus capsid assembly modulator) safety, antiviral activity and pharmacokinetics in patients with chronic hepatitis B (CHB) (Phase 1b, NCT03439488). Methods Twenty treatment-naive, HBeAg-positive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6900488c11a23f8eb2830d1323c9b205
https://pubmed.ncbi.nlm.nih.gov/35040959
https://pubmed.ncbi.nlm.nih.gov/35040959
Autor:
Matthew W. McClure, Christian Schwabe, Thomas N. Kakuda, Lawrence M. Blatt, John Fry, Edward Gane, Catherine A.M. Stedman, Leen Vijgen, Sushmita Mukherjee Chanda
Publikováno v:
Hepatology. 68:2145-2157
This open-label, phase IIa study assessed the safety, pharmacokinetics, and efficacy of direct-acting antiviral agent (DAA) regimens in patients with chronic hepatitis C virus (HCV) infection. Multiple 6-12-week oral regimens of 400-800 mg once daily
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3b4f8a3d32c10bf33870b5752746e84
https://doi.org/10.1002/hep.30126
https://doi.org/10.1002/hep.30126
Autor:
Sofie Deleu, Kurt Spittaels, Thomas N. Kakuda, Lorant Leopold, Vera Hillewaert, Jurgen Vercauteren, Amy Lwin, Richard M. W. Hoetelmans
Publikováno v:
British Journal of Clinical Pharmacology. 84:2663-2672
AIMS: The aim of this study was to evaluate the drug–drug interaction between pimodivir, a novel, non‐nucleoside polymerase basic protein 2 (PB2) subunit inhibitor of the influenza A virus polymerase complex, and oseltamivir, to assess the feasib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3564656db8be8ae61d03fffc94c97ea9
https://doi.org/10.1111/bcp.13733
https://doi.org/10.1111/bcp.13733
Autor:
Sivi Ouwerkerk-Mahadevan, Eric Lawitz, Thomas N. Kakuda, Maria Beumont, Mark S. Sulkowski, O. Khalid, William B. Smith, V. Van Eygen, Leen Vijgen, R. Ghalib, Jordan J. Feld, P. Van Remoortere, M. Gamil, A. Corregidor, Donghan Luo, Franco Felizarta
Publikováno v:
Journal of Viral Hepatitis. 25:631-639
The phase 2, open-label ACCORDION (ClinicalTrials.gov: NCT02349048) study investigated the efficacy, safety and pharmacokinetics of a 6- or 8-week regimen of simeprevir, daclatasvir and sofosbuvir in treatment-naïve patients with chronic hepatitis C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a881120c5a4ddaaaaa27d89fc389794b
https://doi.org/10.1111/jvh.12853
https://doi.org/10.1111/jvh.12853